Epimedium and Its Flavonoids as Multi-Target Anti-Aging Agents: A Systematic Review of Preclinical and Clinical Evidence

Aging arises from numerous biological influences, including genetic factors, oxidative stress, metabolic imbalance, immune dysregulation, and alterations in sex hormones. This review summarizes how Epimedium may slow aging by examining six major dimensions: gene-related actions, antioxidant capacity, metabolic effects, immune modulation, hormone-related regulation, and clinical performance.Through an extensive survey of existing research, the goal was to identify the possible pharmacological pathways through which Epimedium contributes to delayed aging.Published evidence concerning Epimedium’s uses across multiple bodily systems and possible mechanistic bases was assessed using a systematic, integrative approach. The review focuses on gene-associated processes, antioxidation, metabolic regulation, immune activity, hormonal effects, as well as clinical benefit and safety considerations.Flavonoids—including Epimedins A, B, C, and icariin—appear to represent the principal anti-aging agents in Epimedium. Its potential to delay aging seems linked to gene modulation, antioxidant activity, metabolic adjustment, immune responses, and endocrine-related regulation. No serious adverse events have been documented.Epimedium exhibits promising anti-aging properties and is widely employed in China for conditions associated with aging; nonetheless, broader and more rigorous studies are still required.